Abstracts tagged "Myopathies"

Abstract Number: 2074 • ACR Convergence 2024
Experience on the Use of Obinutuzumab off Label in Patients with Refractory Idiopathic Inflammatory Myopathy
Ivana Ilic¹ and Galina Marder², ¹Northwell, Brooklyn, NY, ²Donald and Barbara Zucker School of Medicine at Hofstra/ Northwell, Great Neck, NY
Background/Purpose: Idiopathic inflammatory myopathy (IIM) is a rare multisystem inflammatory condition leading to significant disability. The management of IIM remains challenging. B cell targeting therapies are…
Abstract Number: 0319 • ACR Convergence 2024
Sporadic Inclusion Body Myositis Novel Autoantibody and Biomarker Research Utilizing Proteome Microarray and Mass Spectrometry Proteomics Analysis
Farbod Moghaddam¹, Mark Tarnopolsky², Valérie Leclair³, marie Hudson³, Ross Mitchell⁴, Katherine Buhler¹, Erin Hatcher⁵, Meifeng Zhang¹, Antoine Dufour¹, Luiz de Almeida¹, Marvin Fritzler⁶ and May Choi¹, ¹University of Calgary, Calgary, AB, Canada, ²McMaster University, Hamilton, ON, Canada, ³McGill University, Montreal, QC, Canada, ⁴University of Alberta, Edmonton, Canada, ⁵McMaster University, Hamilton, Canada, ⁶Mitogen Diagnostics Corp, Calgary, AB, Canada
Background/Purpose: Sporadic inclusion body myositis (sIBM) is often challenging to diagnose because many patients have no known biomarkers (seronegative). Machine learning was applied to identify…
Abstract Number: 1160 • ACR Convergence 2024
Short Form-36 Psychometric Properties in Idiopathic Inflammatory Myopathies: Reliability, Validity and Responsiveness
shiri keret¹, Anushka Aggarwal², Maha Almackenzie³, Tanya Chandra⁴, Raisa Silva⁵, Eugenia Gkiaouraki⁶, Nantakarn Pongtarakulpanit⁷, shreya Sriram⁶, Chester Oddis⁷ and Rohit Aggarwal⁸, ¹Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ²Department of Rheumatology, Indraprastha Apollo Hospital, New delhi, NY, ³Division of Rheumatology, Department of Medicine, Medical Cities of the Ministry of the Interior Riyadh, Saudi Arabia, Arlington, VA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: The quality of life, as measured by the Short Form-36 (SF-36), is reduced in patients with idiopathic inflammatory myopathies (IIM). Although endorsed by the…
Abstract Number: 2076 • ACR Convergence 2024
Comparing the Efficacy of Conventional Immunosuppression and Rituximab in Anti-SRP Myositis: Insights from a Tertiary Care Centre Experience
ABHILASHA ARVIND MANWATKAR¹, Ajith Sivadasan², adinair Vijakrishnan², John Antony Jude Prakash³, chandhu aS⁴, JOHN KUMAR DAS⁵, Meera S N², illiasul Ibad k² and JOHN MATHEW¹, ¹christian medical college, vellore, Tamil Nadu, India, ²Christian Medical College, vellore, ³Chritian Medical College, Vellore, ⁴CMC Vellore, Vellore, Tamil Nadu, India, ⁵Christian Medical College, Vellore, India
Background/Purpose: There is a relative scarcity of studies on the effective management of Anti-signal recognition particle (anti-SRP) myositis. Recent consensus on anti-SRP myositis shows that…
Abstract Number: 0327 • ACR Convergence 2024
Clinical and Immunological Risk Factors Associated with Fybromialgia in Patients with Idiopathic Inflammatory Myopathies
Samuel Govea-Peláez¹, Beatriz Alcalá-Carmona², Jennifer Balderas Miranda³, Yatzil Reyna-Juárez², María José Ostos-prado², Nancy R Mejía-Domínguez², Guillermo Juarez-Vega⁴, Jiram Torres Ruiz⁵ and Diana Gomez-martin⁶, ¹INCMNSZ, Mexico City, Mexico, ²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, ³Universidad Nacional Autónoma de México, Ciudad de México, Mexico, ⁴Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, ⁵INCMNSZ, Mexico, Federal District, Mexico, ⁶INCMNSZ, Mexico City, Federal District, Mexico
Background/Purpose: Patients with idiopathic inflammatory myopathies (IIM) have reported chronic pain despite having normal serum muscular enzymes, physician global assessment (PhGA) and MMT8 scores, thus…
Abstract Number: 1161 • ACR Convergence 2024
Characterization of the Clinical Presentation of Idiopathic Inflammatory Myopathies According to the Profile of Specific Autoantibodies with Multiple Positivity
Adriana Miguel-Álvarez¹, luis M Amezcua Guerra², María L Loredo-Mendoza¹, Luis H. Silveira Torre³ and Angélica Vargas Guerrero⁴, ¹Instituto Nacional de Cardiología "Ignacio Chávez", México, Distrito Federal, Mexico, ²Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico, ³Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, ⁴Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico
Background/Purpose: The aim of this study is to assess if there are clinical and serological differences in patients with idiopathic inflammatory myopathies (IIM) according to…
Abstract Number: 2078 • ACR Convergence 2024
Increased RAGE Expression in Myositis
Madison King¹, Rita Spathis², Elizabeth Bagley¹ and Melissa Morales³, ¹Binghamton University, Johnson City, NY, ²Binghamton University School of Pharmacy and Pharmaceutical Sciences, Johnson City, NY, ³SUNY Binghamton, Johnson City, NY
Background/Purpose: Myositis is a broad term for a group of rare autoimmune diseases that cause persistent muscle inflammation, weakness, and fatigue. Currently, first-line treatment for…
Abstract Number: 0332 • ACR Convergence 2024
Predictors of Long-term Radiographic Changes in Patients with Idiopathic Inflammatory Myopathies Using Quantitative Imaging Analysis: Real World Experience from a Single Center Longitudinal Cohort
Sangmee Bae¹, Daniela Macrovic², Auguestine Chung², Jessica Channick², Andrea Oh¹, Jennifer Wang¹, Ani Shahbazian², Tiffany De Leon², Yuna Lee², Grace Kim², Donald Tashkin², Jonathan Goldin² and christina Charles-Schoeman³, ¹UCLA, Los Angeles, CA, ²UCLA, Los Angeles, ³UCLA Medical Center, Santa Monica, CA
Background/Purpose: Interstitial lung disease (ILD) is a major cause of mortality in idiopathic inflammatory myopathies (IIM), and high-resolution computed tomography (HRCT) is a key modality…
Abstract Number: 1164 • ACR Convergence 2024
IVIG Treatment Duration in Immune-mediated Necrotizing Myopathy and a Possible Association of Vacuolar Changes with Black/African American Female Patients
Asim Mohamed¹, Liron Caplan² and Melissa Griffith³, ¹PGY5, Aurora, CO, ²Rocky Mountain Regional VAMC, Aurora, CO, ³University of Colorado, Aurora, CO
Background/Purpose: Immune Mediated Necrotizing Myopathy (IMNM) is a debilitating but understudied entity. Correlations of demographic and clinical features with pathological findings remain underexplored. In addition,…
Abstract Number: 2079 • ACR Convergence 2024
Understanding Relapse Patterns in Anti-HMGCR Statin-induced IMNM: A Detailed Comparative Study
Silvia Grazzini¹, Angeles Galindo-Feria², Edoardo Conticini¹, Ingrid Lundberg³ and Maryam Dastmalchi⁴, ¹Università di Siena, Siena, Italy, ²Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ³Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ⁴Karolinska University hospital, Stockholm, Sweden
Background/Purpose: Statin-induced immune-mediated necrotizing myopathy (IMNM) is a recently recognized subtype of idiopathic inflammatory myopathy (IIM). This condition is marked by the sudden onset of…
Abstract Number: 0333 • ACR Convergence 2024
Predictors of Transplant-Free Survival in Idiopathic Inflammatory Myopathies- associated Interstitial Lung Disease
shiri keret¹, Raisa Silva², Irada Choudhuri², Eugenia Gkiaouraki³, Tanya Chandra⁴, Nantakarn Pongtarakulpanit⁵, shreya Sriram³, silvia Martinez Laverde³, Dana Ascherman³, Siamak Mogahadam⁵, Chester Oddis⁵ and Rohit Aggarwal⁶, ¹Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ²Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Lung involvement is the most common and severe extra-muscular manifestation of Idiopathic Inflammatory Myopathies (IIM). Early identification of patients at risk for lung transplant…
Abstract Number: 1167 • ACR Convergence 2024
Construction of a Refractory Myositis Predictive Index (ReMPI) in a Cohort of Patients with Idiopathic Inflammatory Myopathies
Andres Gaytan Garcia de Alba¹, Nancy R Mejía-Domínguez¹, Yatzil Reyna-Juárez¹, Beatriz Alcalá-Carmona¹, María José Ostos-prado¹, Agustin Hernandez Lopez¹, Diana Gomez-martin² and Jiram Torres Ruiz³, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, ²INCMNSZ, Mexico City, Federal District, Mexico, ³INCMNSZ, Mexico, Federal District, Mexico
Background/Purpose: An important proportion of patients with Idiopathic inflammatory myopathies (IIM) are at risk of developing refractory disease, which predispose them to cumulate damage, treatment…
Abstract Number: 2080 • ACR Convergence 2024
HLA-DRB1*11:01 Association Differenciates Anti-hmgcr Immune-mediated Necrotizing Myopathy from Non-immune Mediated Statin Myotoxicity
Cristina Corrales Selaya¹, Diana Prieto-Peña², gonzalo Ocejo-Viñals³, Carmen Secada Gómez⁴, alfonso Corrales-Martínez⁵, Carmen Ibarbia⁶, Zaida Salmón-gonzalez⁶, Marta Martín-millan⁶, Virginia Portilla-González⁶, Nerea mota-perez⁶, M. sebastian-mora gil⁶, J.C Batista-liz⁶, Veronica Pulito-Cueto⁷, Raquel Lopez-mejias⁷, Ricardo Blanco-Alonso⁸ and Jose Luis Hernandez⁶, ¹Rheumatology, Marques de Valdecilla University Hospital. IDIVAL, Santander, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Department of Immunology, Marqués de Valdecilla University Hospital (HUMV), Santander, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁵Hospital Universitario Marques de Valdecilla, Santander, Spain, ⁶Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁷IDIVAL, Santander, Spain, ⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Genetic risk factors may explain why only a small proportion of patients taking statins develop severe cases of anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) immune-mediated necrotizing myopathy…
Abstract Number: 0337 • ACR Convergence 2024
Characterization of Statin Induced Myopathy in the Hospital Setting
Olivia Yang¹, KUMAR VENKAT², Jeffery Durbin³ and Scott Kubomoto¹, ¹Riverside Community Hospital, Riverside, CA, ²Voluntary Clinical Associate Professor of Medicine -UCRSOM, Riverside, California, IRVINE, CA, ³HCA Healthcare Physicians Services Group, Brentwood, TN
Background/Purpose: Adverse effects of statin use involve the muscle and related rhabdomyolysis. Known risk factors for rhabdomyolysis include female sex, older age, Asian race, hypothyroidism,…
Abstract Number: 1169 • ACR Convergence 2024
Efficacy of Intravenous Immunoglobulin (Octagam 10%) on Pulmonary Manifestations in Patients with Dermatomyositis: Results from the ProDERM Study
Rohit Aggarwal¹, christina Charles-Schoeman² and Joachim Schessl³, and the ProDERM Investigators, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ²UCLA Medical Center, Santa Monica, CA, ³Friedrch-Baur-Institut; Ludwig-Maximilians University of Munich, Munich, Germany
Background/Purpose: Interstitial lung disease (ILD) and other pulmonary manifestations are a major cause of mortality and morbidity in patients with dermatomyositis (DM). The ProDERM study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].